` 2171 (CARsgen Therapeutics Holdings Ltd) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

2171
vs
H
Hang Seng (Hong Kong)

Over the past 12 months, CARsgen Therapeutics Holdings Ltd has significantly outperformed Hang Seng (Hong Kong), delivering a return of +67% compared to the Hang Seng (Hong Kong)'s +28% growth.

Stocks Performance
2171 vs Hang Seng (Hong Kong)

Loading
2171
Hang Seng (Hong Kong)
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
2171 vs Hang Seng (Hong Kong)

Performance Gap Between 2171 and HSI
HIDDEN
Show

Performance By Year
2171 vs Hang Seng (Hong Kong)

Loading
2171
Hang Seng (Hong Kong)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
CARsgen Therapeutics Holdings Ltd vs Peers

Hang Seng (Hong Kong)
2171
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

CARsgen Therapeutics Holdings Ltd
Glance View

Market Cap
8.8B HKD
Industry
Biotechnology

CARsgen Therapeutics Holdings Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of CAR-T cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 573 full-time employees. The company went IPO on 2021-06-18. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The firm have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The firm conducts its businesses in China and the United States.

CARsgen Therapeutics Holdings Ltd Intrinsic Value
HIDDEN
Show
Back to Top